Diabetes 2013 July-20


Efficiency of noopept in streptozotocin-induced diabetes in rats.

Bull Exp Biol Med. 2013, 154(3): 334-338

V.V. Zakusov State Institute of Pharmacology, RussianAcademy of Medical Sciences, Moscow, Russia.

PMID: 23484194


Problem. Diabetes is present in more than 165 million individuals worldwide and has increasingly became a significant health concern. According to the prognosis of International Diabetic Federation by the year 2025 more than 334 million individuals will be afflicted by diabetes. Diabetes is a multifactorial pathology: along with insulin resistance wide spectrum of other metabolic disorders such as oxidative stress, proinflammatory molecules accumulation, deficiency of neurotrophic factors are known to be involved in its pathogenesis. It prompts the search for potential antidiabetic medication among the peptides known to be a multitarget agents. Dipeptides attract the particular attention because of their high biological stability and the existence of a specific system for their transport through membranes (Sala_Rabanal, M., et al., J. Physiol., 2006, 574: 149–166 )

Results. Dr. Rita Ostrovskaya and colleagues evaluated for the first time the effect of novel cognitive enhancing and neuroprotective dipeptide Noopept (ethyl ether of N-phenylacetyl L-prolilglycine; Seredenin S.B et al., US Patent 1995. № 5.439.930; Gudasheva TA et al., Eur J Med Chem 1996, 31(2): 151-157) on the streptozotocine-induced model of diabetes using as indicators the time course of hyperglycemia, of body weight loss and increased pain sensitivity. Noopept was shown to attenuate the degree of abovementioned diabetes’ manifestations in all treatment regimes: preventive, therapeutic, postponed. It should be emphasized that this substituted dipeptide was effective in case of both parenteral and peroral routes of administration. Antioxidant activity of Noopept (Pelsman A. et al., Int. J. Devl Neuroscience 2003, 21:  117–124), as well as its NGF-mimetic effect ( Ostrovskaya R. Bull Exp Biol Med. 2008, 146: 334-337) and anti-inflammatory activity (Alekseeva SV et al., Eksp Klin Farmakol. 2012; 75(9): 25-27) supposed to contribute to antidiabetic effect of this dipeptide.

Impact. These results combined with pharmacokinetic data on Noopept peroral availability and good tolerability demonstrated by its long term clinical usage as a cognition enhancer (www.noopept.ru) raise a possibility to employ this dipeptide for the prevention of diabetes development.


Rita Ostrovskaya-2


Multiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier SchönmannMultiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier Schönmann